Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for vTv Therapeutics Inc. (VTVT : NSDQ)

• Company Description    vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $0.45 Daily Weekly Monthly 20 Day Moving Average: 257,011 shares Shares Outstanding: 90.04 (millions) Market Capitalization: $40.85 (millions) Beta: -1.43 52 Week High: $2.88 52 Week Low: $0.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -43.07% -37.67% 12 Week -43.99% -37.05% Year To Date -54.40% -44.29%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3980 PREMIER DR SUITE 310 - HIGH POINT,NC 27265 USA ph: 336-841-0300 fax: 336-841-0310 ir@vtvtherapeutics.com http://www.vtvtherapeutics.com

• General Corporate Information    Officers Richard S. Nelson - Acting Chief Executive Officer Robin E. Abrams - Executive Chairperson Barry Brown - Chief Accounting Officer John A. Fry - Director Hersh Kozlov - Director Peer Information vTv Therapeutics Inc. (CORR.) vTv Therapeutics Inc. (RSPI) vTv Therapeutics Inc. (CGXP) vTv Therapeutics Inc. (BGEN) vTv Therapeutics Inc. (GTBP) vTv Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 918385105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/03/22 Share - Related Items Shares Outstanding: 90.04 Most Recent Split Date: (:1) Beta: -1.43 Market Capitalization: $40.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.22 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 8.14 EPS Growth vs. Year Ago Period: -11.11% vs. Previous Quarter: -25.00% Sales Growth vs. Year Ago Period: 102.63% vs. Previous Quarter: 22,122.22% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -55.69 12/31/21 - -58.31 09/30/21 - -33.68 Current Ratio 03/31/22 - 1.07 12/31/21 - 1.84 09/30/21 - 4.02 Quick Ratio 03/31/22 - 1.07 12/31/21 - 1.84 09/30/21 - 4.02 Operating Margin 03/31/22 - -273.99 12/31/21 - -346.97 09/30/21 - -68.55 Net Margin 03/31/22 - -313.93 12/31/21 - -324.27 09/30/21 - -46.27 Pre-Tax Margin 03/31/22 - -416.76 12/31/21 - -439.85 09/30/21 - -62.78 Book Value 03/31/22 - -0.09 12/31/21 - -0.11 09/30/21 - -0.24 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©